Back to top
more

Avadel Pharmaceuticals (AVDL)

(Delayed Data from NSDQ)

$11.10 USD

11.10
1,611,449

-0.05 (-0.45%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $11.12 +0.02 (0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (83 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Wall Street Analysts See an 81.61% Upside in Avadel (AVDL): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at an 81.6% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Surging Earnings Estimates Signal Upside for Avadel (AVDL) Stock

by Zacks Equity Research

Avadel (AVDL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Wall Street Analysts Think Avadel (AVDL) Could Surge 97.68%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 97.7% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

All You Need to Know About Avadel (AVDL) Rating Upgrade to Buy

by Zacks Equity Research

Avadel (AVDL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Earnings Estimates Moving Higher for Avadel (AVDL): Time to Buy?

by Zacks Equity Research

Avadel (AVDL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Wall Street Analysts Believe Avadel (AVDL) Could Rally 100.21%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Avadel (AVDL) points to a 100.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz

by Zacks Equity Research

The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy.

Zacks Equity Research

Are Medical Stocks Lagging DaVita (DVA) This Year?

by Zacks Equity Research

Here is how DaVita HealthCare (DVA) and Avadel (AVDL) have performed compared to their sector so far this year.

Zacks Equity Research

Does Avadel (AVDL) Have the Potential to Rally 43.6% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Avadel (AVDL) points to a 43.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Harrow (HROW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Wall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Here's Why You Should Invest in Avadel (AVDL) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.

Zacks Equity Research

Avadel (AVDL) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

How Much Upside is Left in Avadel (AVDL)? Wall Street Analysts Think 37.36%

by Zacks Equity Research

The consensus price target hints at a 37.4% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Why Avadel Pharmaceuticals (AVDL) Stock Might be a Great Pick

by Zacks Equity Research

Avadel Pharmaceuticals (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Will Humana (HUM) Q2 Earnings Beat on Strong Pharmacy Business?

by Zacks Equity Research

Humana's (HUM) second-quarter results are likely to reflect rising premiums and investment income.

Zacks Equity Research

Wall Street Analysts Think Avadel (AVDL) Could Surge 106%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 105.6% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Do Options Traders Know Something About Avadel (AVDL) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Avadel (AVDL) stock based on the movements in the options market lately.

Zacks Equity Research

Implied Volatility Surging for Avadel (AVDL) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Avadel (AVDL) stock based on the movements in the options market lately.

Zacks Equity Research

Avadel (AVDL) Surges: Stock Moves 7.8% Higher

by Zacks Equity Research

Avadel (AVDL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zacks Equity Research

How Avadel (AVDL) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Avadel (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Avadel (AVDL) Beats on Earnings & Revenue Estimates in Q1

by Zacks Equity Research

Avadel's (AVDL) first quarter 2020 earnings and revenues surpass expectations.

Zacks Equity Research

Is a Beat in Store for Avadel (AVDL) This Earnings Season?

by Zacks Equity Research

On Avadel's (AVDL) Q1 earnings call, investor focus will be on the company's lead candidate, FT218, currently being evaluated to treat excessive daytime sleepiness and cataplexy in narcolepsy patients.

Zacks Equity Research

Avadel's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Avadel Pharmaceuticals.

Zacks Equity Research

Is Avadel Pharmaceuticals (AVDL) Stock a Solid Choice Right Now?

by Zacks Equity Research

Avadel Pharmaceuticals (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.